EGFR and head and neck squamous cell carcinoma: Similarly, Wang et al. [19] performed a kinase-related CRISPR Cas9 library screen to identify vulnerabilities that could sensitize HNSCC cells to EGFR inhibition using erlotinib and gefitinib, which constitute the second generation of EGFR inhibitors, while cetuximab represents the first generation of EGFR inhibitor approved for HNSCC treatment.